Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 6 | History Defined

IONGF: ION Energy is exploring & advancing two prospective lithium brine projects in Mongolia: the Baavhai Uul Project and the Urgakh Naran Project.

By Steven Ralston, CFA OTCQB:IONGF | TSXV:ION READ THE FULL IONGF RESEARCH REPORT

Benzinga

BIOX: Bioceres Crop Solutions to Merge with Marrone Bio Innovations in order to acquire a solid bio-crop protection product portfolio, additional bio-R&D capabilities and other

By Steven Ralston, CFA NASDAQ:BIOX READ THE FULL BIOX RESEARCH REPORT

Benzinga

BTAI: Final Countdown to April 5, 2022 PDUFA Date for BXCL501…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BBLG: Bone Biologics Inks Important Supply Agreement

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT

Benzinga

OPNT: Data from OPNT003 Pharmacodynamic Trial in 2Q22…

By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT

Benzinga

BLRX: 2021 Results

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

Benzinga

RVPH: 2021 Results

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT

Benzinga

Read news from The Economist, FT, and more,
with one subscription

MDNA: No Read-Through for MDNA11 Based on Nektar Failure…

By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT

Benzinga

TLSA: KOL Discussion and SPMS 6-Month Results

By John Vandermosten, CFA NASDAQ:TLSA Introduction

Benzinga

ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga

LGVN: Longeveron Continues to Make Progress

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga

CANG: December Quarter Results Met Expectations, but Soft Revenue Guidance for March Quarter Should Mark a Quarterly Trough for 2022

By T. Moore, CFA NYSE:CANG READ THE FULL CANG RESEARCH REPORT

Benzinga

LPCN: 2021 Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga

BRAG: Bragg Grows Q4 14% Despite German Headwinds, Looks Forward to Canadian Launch

By Lisa Thompson NASDAQ:BRAG READ THE FULL BRAG RESEARCH REPORT

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

WKSP: Worksport updates investors and stakeholders with multiple press releases

By Thomas Kerr, CFA NASDAQ:WKSP READ THE FULL WKSP RESEARCH REPORT

Benzinga

DRIO: Future Brightens with $40M Raise & Sanofi Deal

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT

Benzinga

NOVN: A Banner Year for Novan - 2021 Results

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

Benzinga

APLIF: U.S. DoD to Provide Over US$10 Million in Funding for ATI-1701…

By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

VQS: Expanding Product / Service Offerings; Strengthening Market Positions in Key Geographies

By M. Marin NASDAQ:VQS | TSX:VQS.TO READ THE FULL VQS RESEARCH REPORT

Benzinga

PLX: MAA Submitted

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT

Benzinga

IDBA: During Q4 Shipments to IDEMIA and Other Began to Ramp

By Lisa Thompson NASDAQ:IDBA READ THE FULL IDBA RESEARCH REPORT

Benzinga

SQFT: SPAC Initiative Creates Potential for SQFT to Participate in its Potential Upside

By M. Marin NASDAQ:SQFT READ THE FULL SQFT RESEARCH REPORT

Benzinga

COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT

Benzinga

BBLG: Back Pain Solution Potentially on the Way

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT

Benzinga

ORMP: Moving Multiple Candidates & Studies Forward

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.